Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124463 | 0.85 | MET (0.56) | METMAPK14AXLGCKKDR | |
| SCHEMBL1137206 | 0.80 | MET (0.47) | METKDRBRAF | |
| SCHEMBL1137246 | 0.79 | MET (0.46) | METKDRBRAF | |
| SCHEMBL1137374 | 0.77 | MET (0.76) | METAXLKDRBRAF | |
| SCHEMBL4822101 | 0.73 | MET (0.49) | METKDR | |
| SCHEMBL4818600 | 0.73 | MET (0.51) | MET | |
| SCHEMBL5176178 | 0.71 | MET (0.59) | METAXL | |
| SCHEMBL1137065 | 0.71 | MET (0.52) | METAXLKDRBRAF | |
| SCHEMBL1137073 | 0.70 | MET (0.66) | METAXLKDRBRAF | |
| SCHEMBL5174786 | 0.70 | MET (0.72) | METAXLKDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | claimed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | claimed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MET 162/4885MAPK14 109/4885AXL 310/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | MET 162/4885MAPK14 109/4885AXL 310/4885 |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MET 162/4885MAPK14 109/4885AXL 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.